Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01120132 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating the Efficacy of Administration of Cyclosporine (Low Dose and High Dose) and Prednisolone Acetate Compared to Its Components and Vehicle in Patients With Allergic Conjunctivitis
A Phase 2 study, sponsored by Fovea Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 716
- Enrollment target
NCT01120132 is a Phase 2 study that has completed, run by Fovea Pharmaceuticals. The registered enrollment target is 716 participants.
The verdict
NCT01120132, a Phase 2 study, has completed, sponsored by Fovea Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 716 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the efficacy and safety of the administration of cyclosporine and prednisolone acetate compared to placebo in the treatment of allergic conjunctivitis.
Interventions
- DRUG Placebo
- DRUG CsA high dose
- DRUG CsA low dose
- DRUG PA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 716 participants |
| Start Date | 2010-05 |
| Est. Completion | 2010-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01120132
The ClinicalTrials.gov registry entry for NCT01120132 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 716 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fovea Pharmaceuticals, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01120132 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01120132 about?
NCT01120132 is a clinical study titled "Study Evaluating the Efficacy of Administration of Cyclosporine (Low Dose and High Dose) and Prednisolone Acetate Compared to Its Components and Vehicle in Patients With Allergic Conjunctivitis". The purpose of this study is to determine the efficacy and safety of the administration of cyclosporine and prednisolone acetate compared to placebo in the treatment of allergic conjunctivitis.
What is the current status of trial NCT01120132?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 716 participants. The study started on 2010-05. Estimated completion is 2010-08.
What interventions are being tested in trial NCT01120132?
The interventions under investigation include: Placebo (DRUG), CsA high dose (DRUG), CsA low dose (DRUG), PA (DRUG).
Who is sponsoring clinical trial NCT01120132?
This trial is sponsored by Fovea Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.